SCHEMBL3011994

SCHEMBL3011994

Cc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4cccc(Br)c4)CC3)n2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
GBA1 P04062 1/20 0.44
L3MBTL1 Q9Y468 4/20 0.41
USP2 O75604 3/20 0.41
LMNA P02545 3/20 0.41
MAPT P10636 1/20 0.41
RECQL P46063 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CYP3A4 P08684 1/20 0.40
GRM5 P41594 1/20 0.40
MBTD1 Q05BQ5 1/20 0.40
L3MBTL3 Q96JM7 1/20 0.40
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3004373 0.92 KMT2A (0.44) MEN1KMT2AGBA1L3MBTL1USP2
SCHEMBL3023540 0.92 KMT2A (0.44) MEN1KMT2AGBA1L3MBTL1USP2
SCHEMBL3007579 0.91 MEN1 (0.46) MEN1KMT2AGBA1L3MBTL1USP2
SCHEMBL3009893 0.91 KMT2A (0.54) MEN1KMT2AGBA1L3MBTL1USP2
SCHEMBL3017881 0.91 KMT2A (0.48) MEN1KMT2AGBA1L3MBTL1USP2
SCHEMBL3011321 0.91 MEN1 (0.43) MEN1KMT2AGBA1L3MBTL1USP2
SCHEMBL3005969 0.90 GBA1 (0.44) MEN1KMT2AGBA1L3MBTL1USP2
SCHEMBL3015471 0.90 USP2 (0.44) MEN1KMT2AGBA1L3MBTL1USP2
SCHEMBL3012672 0.90 KMT2A (0.50) MEN1KMT2AGBA1L3MBTL1USP2
SCHEMBL3014551 0.90 MAPT (0.49) MEN1KMT2AGBA1L3MBTL1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MEN1 454/4885KMT2A 2680/4885GBA1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.